Chiron

PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Infectious Diseases, Health Technology, Pharmaceutical, Biotechnology, MSD, Research, Clinical research, Government, Congress, Global health, Policy, Cancer, University, Infection, Former, Injection, Emerita, SAB, Immune system, Therapy, Use, Multimedia, Vaccine, Chiron, Medical director

The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.

Key Points: 
  • The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.
  • View the full release here: https://www.businesswire.com/news/home/20240401778401/en/
    In the countries highlighted, PharmaJet has commercial and development partners for prophylactic vaccines for the prevention of infectious diseases as well as cancer treatments.
  • To date, more than 10 million vaccinations have been made and PharmaJet has over 80 global development partners.
  • To find out how this innovative technology can help your vaccine or therapeutic program, schedule a meeting with one of our company experts by clicking here .

Barrett-Jackson Holds Record-Breaking 2024 Scottsdale Auction with $207.6 Million in Total Auction Sales, Most in Company History

Retrieved on: 
Wednesday, January 31, 2024
Retail, Events, Concerts, Other Consumer, Other Automotive, Celebrity, Philanthropy, Other Entertainment, Performance & Special Interest, Luxury, Music, Fund Raising, Foundation, Automotive, Entertainment, Consumer, Emerald, Multimedia, Castrol, Boy Scouts, JDRF, Arizona Lottery, Scouting in Arizona, Bugatti, Ford, Amyloidosis, History, Pinewood derby, WestWorld, Z06, Honeywell, Student, Corvette, No Reserve, Calendar, Research, Gala, Chip, Rock, Mercedes-Benz 300 SL, Future, Jeep, Chiron, Auction

In dynamic fashion, the event featured its largest auction docket in company history with 2,016 collectible vehicles, all selling with No Reserve, for $200.9 million in auction sales.

Key Points: 
  • In dynamic fashion, the event featured its largest auction docket in company history with 2,016 collectible vehicles, all selling with No Reserve, for $200.9 million in auction sales.
  • Additionally, Barrett-Jackson sold 1,180 pieces of authentic automobilia for $6.7 million, bringing total auction sales to $207.6 million, the most for a single auction in Barrett-Jackson history, with a 100 percent sell-through rate and over 190 world-record auction sales.
  • Top auction sales included a 1956 Mercedes-Benz 300SL Gullwing ( Lot #1406 ) for $3.41 million and a 2018 Bugatti Chiron ( Lot #1378 ) for $2.97 million.
  • View the full release here: https://www.businesswire.com/news/home/20240131572922/en/
    Top auction sales during the Barrett-Jackson Scottsdale Auction included a 1956 Mercedes-Benz 300SL Gullwing (Lot #1406) for $3.41 million.

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

Retrieved on: 
Friday, December 1, 2023
MedImmune, Skin, Research and development, Organization, Food, Public key certificate, RNA interference, Physician, Royal college, Squamous-cell carcinoma, Molecular biology, McGill University, Internal medicine, Therapy, University, Harvard Medical School, Development, Drug development, Pharmaceutical industry, Chiron

and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

Key Points: 
  • and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.
  • Dr. Lebel enters this new role after serving as Senior Vice President for preclinical and clinical development since July 2023.
  • "I am honored to lead Sirnaomics' RNAi pipeline through clinical development, building upon my experiences with the Company, and with outside investigators and international regulatory bodies, I hope my experiences of successfully achieving eight product marketing approvals will bring Sirnaomics to the commercial stage," said Dr. Lebel, M.D., Chief Medical Officer of Sirnaomics.
  • His most recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer Spectrum, where he was responsible for Preclinical and Clinical Development, Regulatory Affairs and Pharmacovigilance/Drug Safety.

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
Thursday, November 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

DV8 Infosystems & MindHYVE.ai Announces $140M Valuation After Significant Funding Round by Teller Systems

Retrieved on: 
Tuesday, September 19, 2023
DevOps, Insurance, Partnership, Education, Health, Law enforcement, DV8, Language, Teller system, Organization, Engineering, AI, Software, Customer service, Medical device, Sales, Management, Chiron

IRVINE, Calif., Sept. 19, 2023 /PRNewswire/ -- DV8 Infosystems the IT services firm and MindHYVE.ai the creators of the Enterprise Grade AI Fabric, today announced a significant move in the evolving world of enterprise grade AI solutions for software, cloud and cyber security. Teller Systems set an enterprise valuation of over $140 million on DV8 Infosystems and it's AI subsidiary, MindHYVE.ai through a private investment round in the company.

Key Points: 
  • Teller Systems set an enterprise valuation of over $140 million on DV8 Infosystems and it's AI subsidiary, MindHYVE.ai through a private investment round in the company.
  • This strategic investment by Teller Systems, a global AI software investor, underscores the immense transformative potential of DV8 Infosystems and its subsidiary, MindHYVE.ai.
  • Both Teller Systems and DV8 Infosystems are poised to redefine the boundaries of what businesses can achieve with the power of enterprise grade AI fabrics and AI 'agents' integrated into organizations worldwide.
  • MindHYVE.ai, a creation of DV8 Infosystems, builds and deploys an enterprise grade AI fabric upon which businesses can transform their operations.

Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development

Retrieved on: 
Wednesday, September 13, 2023
King's Cross, Faculty, Drug development, University, NMT, Cancer research, Hook effect, Drug, Emergent, MBA, Faculty of Pharmaceutical Medicine, Novartis, Daiichi Sankyo, ESCP Business School, ADC, Spacecraft, IND, Pharmaceutical medicine, Pharmaceutical industry, Fine chemical, Chiron

LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.

Key Points: 
  • LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
  • In this new role, Dr. McLeod joins the Leadership Team and will be responsible for developing the clinical strategy and IND submissions as the company advances its targeted ADC pipeline towards clinical trials.
  • Welcoming Robert to the company, Myricx CEO Dr. Robin Carr said: “We are very pleased to have attracted Robert to the company.
  • In addition, in line with its strategy to focus on the development of NMT inhibitors as novel cytotoxic payloads for ADCs, the Company has recently rebranded from Myricx Pharma to Myricx Bio.

CELEBRATED AUTO DESIGNER SASHA SELIPANOV LAUNCHES HARDLINE27, A DESIGN AND BRANDING CONSULTANCY

Retrieved on: 
Thursday, August 3, 2023
Essentia, Gemera, Hardline, Bugatti Chiron, Beauty, Interior (topology), Marketing, Eye, CAD, Nonsense, University for the Creative Arts, Huracan, Chiron, Volkswagen, Chevrolet, Education minister, LOS, Transport, Fashion design, Industrial design, Lamborghini, Bugatti, Koenigsegg

LOS ANGELES, Aug. 3, 2023 /PRNewswire/ -- Renowned sports car designer Sasha Selipanov announces the formation of Hardline27, a new automotive design and branding studio with operations in Berlin and Los Angeles. Designing for global clients, Hardline27 will provide 360° expertise in automotive design and brand-consulting services.

Key Points: 
  • Hardline27 harnesses in-house design expertise from industry powerhouses with an innovative all-digital approach to design.
  • Hardline27 is equipped with an all-star team of designers and automotive experts in design, branding and marketing all hand-picked by Selipanov.
  • Sasha Selipanov's illustrious, two-decade automotive design career began at Volkswagen and Lamborghini, followed by leading roles at Bugatti (Head of Exterior Design), Genesis (Head of Advanced Design) and Koenigsegg (Head of Design).
  • Selipanov earned his degree in transportation design from the Art Center College of Design in Pasadena, CA.

Chiron Investigations Offers Effortless Recovery Solutions for Stolen Crypto Assets

Retrieved on: 
Tuesday, May 9, 2023
Crime, Human, Theft, Interview, Cryptocurrency, Chiron, UNITED KINGDOM

With a proven track record of success and having handled hundreds of cases, Chiron Investigations is recognized for its swift and effective cryptocurrency recovery services.

Key Points: 
  • With a proven track record of success and having handled hundreds of cases, Chiron Investigations is recognized for its swift and effective cryptocurrency recovery services.
  • Victims of bitcoin theft can now rely on Chiron Investigations to recover their lost digital assets, including how to get their stolen crypto back.
  • In a recent interview, the IT head of Chiron Investigations emphasized the company's commitment to providing competent and efficient recovery services, recognizing the significance of these assets to their clients.
  • Overall, Chiron Investigations' crypto recovery services to help get stolen bitcoin back are revolutionizing the sector by offering the crucial backing and help needed to do so.

Count on Chiron Investigations for Swift and Dependable Cryptocurrency Retrieval Services

Retrieved on: 
Wednesday, May 3, 2023
Human, Partnership, Law enforcement, Fear, Crime, Organization, Philosophy, Commerce, Root cause analysis, CFO, Risk management, Cryptocurrency, Management, Chiron, UNITED KINGDOM

Chiron Investigations acknowledges the severe impact of online crime on the reputation, operations, and finances of organizations.

Key Points: 
  • Chiron Investigations acknowledges the severe impact of online crime on the reputation, operations, and finances of organizations.
  • Chiron Investigations offers a suite of services aimed at helping businesses prevent and recover from online crime.
  • "Our philosophy is to offer a holistic solution that encompasses all aspects of online crime," commented the spokesperson for Chiron Investigations.
  • For more information about Chiron Investigations and their services, visit their website at www.chiron-investigations.com

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

Retrieved on: 
Wednesday, April 26, 2023
LSE, Adverum Biotechnologies, Oxford Biomedica, Tenaya, Chapman University, Chapter Seven, LR, Business, Certified Public Accountant, OXB, VaxGen, CDMO, Novartis, Saint Mary's College, Growth, KPMG, Pharmaceutical industry, Vaccine, Chiron

Oxford, UK – 26thApril 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director.

Key Points: 
  • Oxford, UK – 26thApril 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director.
  • Ms Patterson also serves on the Board of Directors for Nkarta (NASDAQ:NKTX), a clinical-stage cell therapy company.
  • Dr. Roch Doliveux, Chair of Oxford Biomedica, said: “The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers.
  • Diadexus voluntarily filed for Chapter 7 bankruptcy in June 2016 while Ms. Patterson was its Chief Financial Officer.